A Review of Resveratrol as a Potent Chemoprotective and Synergistic Agent in Cancer Chemotherapy

Qicai Xiao, Wangshu Zhu, Wei Feng, Su Seong Lee, Albert Wingnang Leung, Jun Shen, Liqian Gao, Chuanshan XuFrontiers in Pharmacology 2019 · DOI

Abstract

Background: Cancer has become a major disease endangering human health around the world. Conventional chemotherapy suffers from many side effects including pain, cardiotoxicity, hepatotoxicity, and renal toxicity. This review aims to describe a natural product of resveratrol as a chemoprotective and synergistic agent in the modulation of cancer chemotherapy. Methods: The publications were identified by comprehensive searching of SciFinder, PubMed, Web of Science, and our own reference library. Search terms included combinations of "resveratrol," "cancer," "natural products," "chemotherapy," and "side effects." Selection of material focused on resveratrol reducing the side effects on cancer chemotherapy. Results: Thirty one references were referred in this review to outline resveratrol as a potent chemoprotective and synergistic agent in cancer chemotherapy, including 22 papers for describing the chemoprotective effects, and 9 papers for illustrating the synergistic effects. Conclusion: This study provides a systematic summary of resveratrol serving as a potent chemoprotective and synergistic agent to reduce the associated-side effects and enhance the therapeutic outcomes in cancer chemotherapy. Further studies in terms of resveratrol on a large amount of preclinical tests and clinical trials are highly demanded.

Introduction

Conventional chemotherapy remains a cornerstone of cancer treatment, yet it is often described as a "double-edged sword." While these drugs are effective at killing rapidly dividing malignant cells, they lack the precision to spare healthy tissue. This lack of selectivity leads to severe systemic toxicities, most notably cardiotoxicity, hepatotoxicity (liver damage), and renal (kidney) failure. These debilitating side effects frequently force clinicians to limit dosages, which can ultimately compromise the overall success of the treatment.

There is an urgent clinical need for "adjuvants"—supplementary compounds that can protect healthy organs without shielding the tumor itself. Resveratrol (RES), a natural polyphenol found in common foods like grapes, berries, and peanuts, has emerged as a promising candidate. This review highlights RES as a powerful "double agent" in oncology: it simultaneously shields healthy organs from the toxic side effects of chemotherapy (chemoprotection) and makes cancer cells more vulnerable to those same drugs (synergy).

Resveratrol is a natural polyphenol found in various fruits, such as berries and grapes.

Methodology

This paper is a systematic review conducted according to rigorous literature search guidelines. The authors performed a comprehensive search across SciFinder, PubMed, and Web of Science, initially identifying 7,678 records. Through a meticulous screening process, the researchers narrowed the selection down to 31 core studies specifically focused on the interaction between resveratrol and chemotherapy.

The methodology prioritized papers demonstrating three primary outcomes: the reduction of chemotherapy-induced side effects, chemoprotective effects against external carcinogens, and synergistic effects that enhanced the therapeutic efficacy of existing drugs. The review synthesizes data from various models, including in vitro cell lines (such as MCF-7 breast cancer cells) and in vivo animal models (such as Wistar rats and CD-1 mice).

Mechanisms of Action: Protection and Sensitization

Resveratrol’s therapeutic potential stems from its ability to modulate multiple biological pathways simultaneously. As shown in the figure below, RES exhibits a wide array of activities, ranging from antioxidant and anti-inflammatory properties to direct chemotherapeutic effects.

The chemical structure of Resveratrol and its multifaceted biological activities, including chemoprotective and chemotherapeutic roles.

The Antioxidant Shield

RES acts as a potent scavenger of Reactive Oxygen Species (ROS). In cardiac tissue, it increases levels of Superoxide Dismutase (SOD), an enzyme that neutralizes the oxidative stress typically caused by drugs like Doxorubicin. By mitigating this oxidative damage, RES helps prevent the cardiotoxicity that often limits the use of anthracyclines.

Selective Sensitization and Enzymatic Modulation

Unlike many antioxidants that might inadvertently protect tumor cells, RES actively interferes with cancer's defense mechanisms. It can arrest the cell cycle in the S-phase, making tumors more susceptible to DNA-damaging agents like 5-Fluorouracil (5-FU). Furthermore, RES inhibits "activating" enzymes (such as CYP19 and CYP1B1) that can convert pro-carcinogens into active cancer-causing agents, while inducing "detoxification" enzymes (like NQO1) that assist the body in clearing toxins.

Key Therapeutic Outcomes

The review identifies several critical areas where RES improves the outcomes of standard chemotherapy:

  • Cardioprotection: RES was found to be the most effective antioxidant among several tested for neutralizing ROS in heart tissue during Doxorubicin treatment.
  • Synergy with Standard Chemotherapy: RES significantly enhanced the anti-tumor effects of 5-FU in murine hepatoma models and sensitized non-Hodgkin’s lymphoma and multiple myeloma cells to paclitaxel.
  • Mitigation of Heavy Metal Toxicity: In treatments involving Arsenic Trioxide ($As_2O_3$), RES facilitated the methylation and excretion of arsenic, significantly reducing kidney and liver toxicity.
  • Pathway Inhibition: RES suppresses the PI3K/AKT and mTORC1 pathways, which are frequently overactive in cancer and contribute significantly to drug resistance.

Challenges and Future Directions

Despite its promise, several hurdles remain before resveratrol can be integrated into standard clinical practice. A primary concern is bioavailability; RES is rapidly metabolized and cleared by the human body, making it difficult to maintain therapeutic concentrations in the bloodstream. Future research must focus on developing RES analogs or specialized delivery systems, such as nanoparticles or peptide conjugates, to improve stability and targeting.

Furthermore, there is a significant "clinical gap." While preclinical data from cell and animal studies are robust, there is a lack of large-scale, phase III clinical trials. Currently, very few clinical records focus specifically on RES as a combinational agent in chemotherapy. While RES is a highly promising candidate for reducing side effects and enhancing therapeutic outcomes, the transition from the laboratory to the pharmacy requires more rigorous human data and advanced drug-delivery engineering.

Summary updated

Abstract

<b>Background:</b> Cancer has become a major disease endangering human health around the world. Conventional chemotherapy suffers from many side effects including pain, cardiotoxicity, hepatotoxicity, and renal toxicity. This review aims to describe a natural product of resveratrol as a chemoprotective and synergistic agent in the modulation of cancer chemotherapy. <b>Methods:</b> The publications were identified by comprehensive searching of SciFinder, PubMed, Web of Science, and our own reference library. Search terms included combinations of "resveratrol," "cancer," "natural products," "chemotherapy," and "side effects." Selection of material focused on resveratrol reducing the side effects on cancer chemotherapy. <b>Results:</b> Thirty one references were referred in this review to outline resveratrol as a potent chemoprotective and synergistic agent in cancer chemotherapy, including 22 papers for describing the chemoprotective effects, and 9 papers for illustrating the synergistic effects. <b>Conclusion:</b> This study provides a systematic summary of resveratrol serving as a potent chemoprotective and synergistic agent to reduce the associated-side effects and enhance the therapeutic outcomes in cancer chemotherapy. Further studies in terms of resveratrol on a large amount of preclinical tests and clinical trials are highly demanded.
BibTeX
@inproceedings{xiao2019review,
  author = {Qicai Xiao and Wangshu Zhu and Wei Feng and Su Seong Lee and Albert Wingnang Leung and Jun Shen and Liqian Gao and Chuanshan Xu},
  title = {{A Review of Resveratrol as a Potent Chemoprotective and Synergistic Agent in Cancer Chemotherapy}},
  booktitle = {Frontiers in Pharmacology},
  year = {2019},
  doi = {10.3389/fphar.2018.01534},
}
Figure